|
![]() |
|
|
Omeprazole
drug data and news
Omeprazole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Omeprazole | ||
| Brand Names/Synonyms | Antra; Antra Mups; Audazol; Aulcer; Belmazol; CCRIS 7099; Ceprandal; Danlox; Demeprazol; Desec; Dizprazol; Dudencer; Elgam; Emeproton; Epirazole; Erbolin; Esomeprazole; Esomeprazole Magnesium; Exter; Gasec; Gastrimut; Gastroloc; Gibancer; H 168/68; HSDB 3575; Indurgan; Inhibitron; Inhipump; Lensor; Logastric; Lomac; Losec; Mepral; Miol; Miracid; Mopral; Morecon; Nexium; Nexium Iv; Nilsec; Nopramin; OMEP; OMEPRAZOLE; OMP; OMZ; Ocid; Olexin; Omapren; Omebeta 20; Omed; Omegast; Omepral; Omeprazol [Inn-Spanish]; Omeprazole; Omeprazole [Usan:Ban:Inn:Jan]; Omeprazolum [Inn-Latin]; Omeprazon; Omeprol; Omesek; Omezol; Omezolan; Omid; Omisec; Omizac; Ompanyt; Ortanol; Osiren; Ozoken; Paprazol; Parizac; Pepticum; Pepticus; Peptilcer; Prazentol; Prazidec; Prazolit; Prilosec; Prilosec Otc; Procelac; Proclor; Prysma; Ramezol; Regulacid; Result; Sanamidol; Secrepina; Tedec Ulceral; Ulceral; Ulcesep; Ulcometion; Ulcozol; Ulcsep; Ulsen; Ultop; Ulzol; Victrix; Zefxon; Zegerid; Zepral; Zimor; Zoltum | ||
| Indication | For the treatment of gastroesophageal reflux disease | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, Omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. | ||
| Mechanism Of Action | Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Omeprazole blocks the final step in acid production, thus reducing gastric acidity. | ||
| Omeprazole News (When available) |
STABILITY OF OMEPRAZOLE SODIUM AND PANTOPRAZOLE SODIUM DILUTED FOR ... Apr 21, 2006 'Medicare Part D': What the Benefit Means For Medical Technology May 15, 2006 EXCELLUS BLUECROSS BLUESHIELD LAUNCHES CAMPAIGN TO HELP CONSUMERS ... May 15, 2006 Santarus Reports First Quarter 2006 Financial Results; Conference ... May 4, 2006 Goitre and reduced acid secretion May 10, 2006 Zentiva NV 1st Quarter Results 2006 May 2, 2006 Nasal spray dependence is a hard habit to break May 10, 2006 Schwarz Pharma First-Quarter Profit Doubles (Update2) Apr 24, 2006 Off-Label Drug Use May 2, 2006 Schwarz Pharma Oper Profit Above Forecast Apr 25, 2006 NSAIDs: Pain Relief or Pain in the Gut? May 2, 2006 Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic ... Apr 26, 2006 A method for weaning yourself off nasal spray May 2, 2006 POZEN Reports First Quarter 2006 Results Apr 27, 2006 Santarus to Present at UBS Global Specialty Pharmaceuticals ... Apr 18, 2006 Santarus to Hold First Quarter 2006 Financial Results Conference ... Apr 24, 2006 Indigestion defined Apr 29, 2006 First Quarter Report 2006: Schwarz Pharma with a Good Start Apr 25, 2006 | ||
| Dosage Forms | Oral tablets | ||
| Drug_Category | Anti-ulcer Agents; Proton-pump Inhibitors; ATC:A02BC01; ATC:A02BC05 | ||
| Absorption | Absorption is rapid, Absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg | ||
| Interactions |
-->Interactions for Omeprazole: Other Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole. Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole. Combination Therapy with Clarithromycin Co-administration of omeprazole and clarithromycin may result in increases in plasma levels of ompeprazole, clarithromycin, and 14-hydroxy-clarithromycin. Concomitant administration of clarithromycin with cisapride, pimozide, or terfenadine is contraindicated. There have been reports of an intereaction between erythromycin and astemizole resulting in QT prolongation and torsades de points. Concomitant administration of erythromycin and astemizole is contraindicated. Because clarithromycin is also metabolized by cytochrome P450, concomitant administration of clarithromycin with astemizole is not recommended. | ||
| Toxicity | confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth, LD50= | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole | ||
| Chemical Formula | C17H19N3O3S | ||
| Molecular Weight | 345.417 g/mol | ||
| Smiles String | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC | ||
| Melting Point | 156°C | ||
| Water Solubility | 82.3 mg/L | ||
| State | white to off-white crystalline powder | ||
| LogP/Hphobicity | 1.166 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 0.5-1 hour | ||
| Protein Binding [%] | 95% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/pri1350.shtml http://www.drugs.com/cons/Omeprazole.html http://www.rxlist.com/cgi/generic/omepra.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00446 | ||
| CAS Registry Number | 73590-58-6 | ||
| KEGG Compound ID | C07324 | ||
| PubChem ID | SID:189970 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2260867 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |